PhilipMartinArlenMD

Oncology • Bethesda, MD

Physician

Join to view full profile

Dr. Arlen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Arlen's full profile

Already have an account?

Office
10 Center Dr
Rm 8b09
Bethesda, MD 20892
Phone+1 301-496-4026
Is this information wrong?

Education & Training

National Cancer Institute1997 - 1999
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1997
Wellstar Health System/Wellstar Atlanta Medical CenterResidency, Internal Medicine, 1991 - 1994
Medical College of Georgia at Augusta UniversityClass of 1991

Certifications & Licensure

GA State Medical License 1992 - 2025
MD State Medical License 1999 - 2024
FL State Medical License 2016 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2002 Aug 01
Completed
Phase 2
Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery Start of enrollment: 2004 Aug 01
Completed
Not Applicable
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1, Phase 2
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Start of enrollment: 2019 Jan 15
Not yet recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.
Shruti U Gandhy, Fatima H Karzai, Marijo Bilusic, Sheri McMahon, Lisa M Cordes, Jennifer Marte, Amy J Weisman, Timothy G Perk, Liza Lindenberg, Esther Mena, Baris Turk...> ;European Urology Oncology. 2023 Oct 17
1 citations
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M Geynisman, Matthew Zibelman, Tina...> ;The Oncologist. 2023 Jul 5
2 citations
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lip...> ;Journal of Experimental & Clinical Cancer Research. 2023 Apr 26
3 citations
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lip...> ;Journal of Experimental & Clinical Cancer Research. 2023 Mar 29
4 citations
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarc...
Brandon M Huffman, Atrayee Basu Mallick, Nora K Horick, Andrea Wang-Gillam, Peter Joel Hosein, Michael A Morse, Muhammad Shaalan Beg, Janet E Murphy, Sharon Mavroukaki...> ;JAMA Network Open. 2023 Jan 3
1 citations
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Massimo Fantini, Philip Martin Arlen, Kwong Yok Tsang> ;Frontiers in Immunology. 2023 Jan 1
1 citations
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201.
Kwong Y Tsang, Massimo Fantini, Anjum Zaki, Sharon A Mavroukakis, Maria Pia Morelli, Christina M Annunziata, Philip M Arlen> ;Cancers. 2022 Oct 12
4 citations
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas.
Kwong Yok Tsang, Massimo Fantini, Sharon A Mavroukakis, Anjum Zaki, Christina M Annunziata, Philip M Arlen> ;Cancers. 2022 Jun 21
9 citations
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
Ravi A. Madan, Fatima Karzai, Renee N. Donahue, Munjid Al-Harthy, Marijo Bilusic, Inger I Rosner, Harpreet Singh, Philip M. Arlen, Marc R. Theoret, Jennifer L. Marte, ...> ;Journal for Immunotherapy of Cancer. 2021 Mar 1
7 citations
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Ravi A. Madan, Fatima Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph Kim, Philip M. Arlen, Inger L. Rosner, Marc R. Theoret, Lisa M. Cordes, Marijo Bilusic, Cody...> ;BJU International. 2021 Apr 1
5 citations
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer
Richard D. Kim, Nilofer S. Azad, Michael A. Morse, Elizabeth Poplin, Amit Mahipal, B. T. Benjamin Tan, Sharon Mavroukakis, Massimo Fantini, Kwong Y. Tsang, Anjum Zaki,...> ;Clinical Cancer Research. 2020 Jul 15
6 citations
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
Kristen P. Zeligs, Maria Pia Morelli, Justin M. David, Monica K. Neuman, Lidia Hernandez, Stephen M. Hewitt, Michelle K. Ozaki, Akosua Osei-Tutu, David E. Anderson, Th...> ;Frontiers in Oncology. 2020 Jun 19
2 citations
Rationale, discovery and clinical development of NEO-201
Philip M. Arlen, Maria Pia Morelli> ;Expert Opinion on Biological Therapy. 2020 Feb 1
20 citations
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
Massimo Fantini, Justin M. David, Hing C Wong, Christina M. Annunziata, Philip M. Arlen, Kwong Y. Tsang> ;Cancer Biotherapy & Radiopharmaceuticals. 2019 Apr 10
18 citations
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.
Massimo Fantini, Justin M. David, Olga Saric, Alexander Dubeykovskiy, Yongzhi Cui, Sharon Mavroukakis, Andrew Bristol, Christina M. Annunziata, Kwong Y. Tsang, Philip ...> ;Frontiers in Immunology. 2018 Jan 4
1 citations
Neoantigens in the immuno-oncology space.
Philip M. Arlen> ;Future Oncology. 2017 Oct 1
37 citations
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.
Andrea B. Apolo, Fatima Karzai, Jane B. Trepel, Sylvia V. Alarcon, Sunmin Lee, Min-Jung Lee, Yusuke Tomita, Liang Cao, Yunkai Yu, Maria J. Merino, Ravi A. Madan, Howar...> ;Clinical Genitourinary Cancer. 2017 Feb 1
13 citations
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.
Muhammad Shaalan Beg, Nilofer S. Azad, Sandip Pravin Patel, Jose R. Torrealba, Sharon Mavroukakis, Melony A. Beatson, XuePing Wang, Philip M. Arlen, Michael A. Morse> ;Cancer Chemotherapy and Pharmacology. 2016 Jul 23
19 citations
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.
Lauren V. Wood, Antonio Tito Fojo, Brenda D. Roberson, Meghan S. B. Hughes, William L. Dahut, James L. Gulley, Ravi A. Madan, Philip M. Arlen, Marianna Sabatino, David...> ;Oncoimmunology. 2016 Jul 1
22 citations
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
Ravi A. Madan, Fatima Karzai, Yang-Min Ning, Bamidele Adesunloye, Xuan Huang, Nancy Harold, Anna Couvillon, Guinevere Chun, Lisa M. Cordes, Tristan M. Sissung, Shaunna...> ;BJU International. 2016 Oct 1
64 citations
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial
Christopher R. Heery, Nuhad K. Ibrahim, Philip M. Arlen, Mahsa Mohebtash, James L. Murray, Kimberly Koenig, Ravi A. Madan, Sheri McMahon, Jennifer L. Marte, Seth M. St...> ;JAMA Oncology. 2015 Nov 1
93 citations
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Christopher R. Heery, B. Harpreet Singh, Myrna Rauckhorst, Jennifer L. Marte, Renee N. Donahue, Italia Grenga, Timothy C. Rodell, William L. Dahut, Philip M. Arlen, Ra...> ;Cancer Immunology Research. 2015 Jun 30
36 citations
A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: E...
Robert S. DiPaola, Yu-Hui Chen, Glenn J. Bubley, Mark N. Stein, Noah M. Hahn, Michael A. Carducci, Edmund C. Lattime, James L. Gulley, Philip M. Arlen, Lisa H. Butterf...> ;European Urology. 2015 Sep 1
Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer
Myron Arlen, Philip Arlen, Gene F. Coppa, Jim Crawford, XuePing Wang, Olga Saric, Alex Dubeykovskiy, Ernesto P. Molmenti> ;World Journal of Gastrointestinal Oncology. 2014 Jun 15
73 citations
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma
Marijo Bilusic, Christopher R. Heery, Philip M. Arlen, Myrna Rauckhorst, David Apelian, Kwong Y. Tsang, Jo A. Tucker, Caroline Jochems, Jeffrey Schlom, James L. Gulley...> ;Cancer Immunology, Immunotherapy. 2014 Mar 1
Join now to see all

Journal Articles

arlen p

Grant Support

Clinical Trials Involving Vaccine And Standard Of Care Cancer TherapiesNational Cancer Institute2008
Vaccine Clinical TrialsNational Cancer Institute2007
Vaccine Clinical TrialsDivision Of Basic Sciences - Nci2005–2006